Replies to post #146476 on Biotech Values

[DewDiligence]

Good to see that someone else knowledgeable in HCV realizes ABT is a beneficiary. This angle was surprisingly missed by everyone on Twitter.

[mcbio]

On a related note, I think people may unduly punish BMY today forgetting daclatasvir, asunaprevir and lambda which still comprise a very enviable HCV portfolio.

How do we know daclatasvir isn't the issue (#msg-78155696 )?